Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosis.
AMR
Bedaquiline
Drug resistance
Phylogenetics
Tuberculosis
Journal
Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844
Informations de publication
Date de publication:
19 Feb 2024
19 Feb 2024
Historique:
received:
06
01
2023
accepted:
19
01
2024
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
19
2
2024
Statut:
epublish
Résumé
Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of Mycobacterium tuberculosis (Mtb) resistant to bedaquiline. Clinical bedaquiline resistance is most frequently conferred by off-target resistance-associated variants (RAVs) in the mmpR5 gene (Rv0678), the regulator of an efflux pump, which can also confer cross-resistance to clofazimine, another TB drug. We compiled a dataset of 3682 Mtb genomes, including 180 carrying variants in mmpR5, and its immediate background (i.e. mmpR5 promoter and adjacent mmpL5 gene), that have been associated to borderline (henceforth intermediate) or confirmed resistance to bedaquiline. We characterised the occurrence of all nonsynonymous mutations in mmpR5 in this dataset and estimated, using time-resolved phylogenetic methods, the age of their emergence. We identified eight cases where RAVs were present in the genomes of strains collected prior to the use of bedaquiline in TB treatment regimes. Phylogenetic reconstruction points to multiple emergence events and circulation of RAVs in mmpR5, some estimated to predate the introduction of bedaquiline. However, epistatic interactions can complicate bedaquiline drug-susceptibility prediction from genetic sequence data. Indeed, in one clade, Ile67fs (a RAV when considered in isolation) was estimated to have emerged prior to the antibiotic era, together with a resistance reverting mmpL5 mutation. The presence of a pre-existing reservoir of Mtb strains carrying bedaquiline RAVs prior to its clinical use augments the need for rapid drug susceptibility testing and individualised regimen selection to safeguard the use of bedaquiline in TB care and control.
Sections du résumé
BACKGROUND
BACKGROUND
Drug resistance in tuberculosis (TB) poses a major ongoing challenge to public health. The recent inclusion of bedaquiline into TB drug regimens has improved treatment outcomes, but this advance is threatened by the emergence of strains of Mycobacterium tuberculosis (Mtb) resistant to bedaquiline. Clinical bedaquiline resistance is most frequently conferred by off-target resistance-associated variants (RAVs) in the mmpR5 gene (Rv0678), the regulator of an efflux pump, which can also confer cross-resistance to clofazimine, another TB drug.
METHODS
METHODS
We compiled a dataset of 3682 Mtb genomes, including 180 carrying variants in mmpR5, and its immediate background (i.e. mmpR5 promoter and adjacent mmpL5 gene), that have been associated to borderline (henceforth intermediate) or confirmed resistance to bedaquiline. We characterised the occurrence of all nonsynonymous mutations in mmpR5 in this dataset and estimated, using time-resolved phylogenetic methods, the age of their emergence.
RESULTS
RESULTS
We identified eight cases where RAVs were present in the genomes of strains collected prior to the use of bedaquiline in TB treatment regimes. Phylogenetic reconstruction points to multiple emergence events and circulation of RAVs in mmpR5, some estimated to predate the introduction of bedaquiline. However, epistatic interactions can complicate bedaquiline drug-susceptibility prediction from genetic sequence data. Indeed, in one clade, Ile67fs (a RAV when considered in isolation) was estimated to have emerged prior to the antibiotic era, together with a resistance reverting mmpL5 mutation.
CONCLUSIONS
CONCLUSIONS
The presence of a pre-existing reservoir of Mtb strains carrying bedaquiline RAVs prior to its clinical use augments the need for rapid drug susceptibility testing and individualised regimen selection to safeguard the use of bedaquiline in TB care and control.
Identifiants
pubmed: 38374151
doi: 10.1186/s13073-024-01289-5
pii: 10.1186/s13073-024-01289-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34Subventions
Organisme : Wellcome Trust
ID : 203583/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 203919/Z/16/Z
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R01356X/1
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
World Health Organization. Global tuberculosis report 2022. (WHO, 2022).
Cegielski JP, et al. Multidrug-resistant Tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis. 2016;62:418–30. https://doi.org/10.1093/cid/civ910 .
doi: 10.1093/cid/civ910
pubmed: 26508515
World Health Organization. Global tuberculosis report 2019. (2019).
Andries K, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223–7. https://doi.org/10.1126/science.1106753 .
doi: 10.1126/science.1106753
pubmed: 15591164
Diacon AH, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371:723–32. https://doi.org/10.1056/NEJMoa1313865 .
doi: 10.1056/NEJMoa1313865
pubmed: 25140958
Food and Drug Administration. SIRTURO approval letter. Retrieved Jan 15, 2024, from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/204384orig1s000ltr.pdf .
Borisov SE. et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur Respir J 2017;49. https://doi.org/10.1183/13993003.00387-2017
Guglielmetti L. et al. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur Respir J 2017;49. https://doi.org/10.1183/13993003.01799-2016
Olayanju O. et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J 2018;51. https://doi.org/10.1183/13993003.00544-2018
Ndjeka N. et al. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur Respir J 2018;52. https://doi.org/10.1183/13993003.01528-2018
World Health Organization. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. (2022).
Conradie F, et al. Bedaquiline-Pretomanid-Linezolid regimens for drug-resistant Tuberculosis. N Engl J Med. 2022;387:810–23. https://doi.org/10.1056/NEJMoa2119430 .
doi: 10.1056/NEJMoa2119430
pubmed: 36053506
pmcid: 9490302
Berry C, et al. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis. Trials. 2022;23:484. https://doi.org/10.1186/s13063-022-06331-8 .
doi: 10.1186/s13063-022-06331-8
pubmed: 35698158
pmcid: 9190445
Paton NI, Cousins C, Suresh C. Treatment strategy for rifampin-susceptible tuberculosis. Reply N Engl J Med. 2023;388:2298. https://doi.org/10.1056/NEJMc2304776 .
doi: 10.1056/NEJMc2304776
pubmed: 37314717
Manson AL, et al. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance. Nat Genet. 2017;49:395–402. https://doi.org/10.1038/ng.3767 .
doi: 10.1038/ng.3767
pubmed: 28092681
pmcid: 5402762
Cohen KA, et al. Evolution of extensively drug-resistant Tuberculosis over four decades: Whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from KwaZulu-Natal. PLoS Med. 2015;12:e1001880. https://doi.org/10.1371/journal.pmed.1001880 .
doi: 10.1371/journal.pmed.1001880
pubmed: 26418737
pmcid: 4587932
Eldholm V, Balloux F. Antimicrobial resistance in Mycobacterium tuberculosis: the odd one out. Trends Microbiol. 2016;24:637–48. https://doi.org/10.1016/j.tim.2016.03.007 .
doi: 10.1016/j.tim.2016.03.007
pubmed: 27068531
Huitric E, et al. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother. 2010;54:1022–8. https://doi.org/10.1128/AAC.01611-09 .
doi: 10.1128/AAC.01611-09
pubmed: 20038615
Almeida D, et al. Mutations in pepQ confer low-level resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;60:4590–9. https://doi.org/10.1128/AAC.00753-16 .
doi: 10.1128/AAC.00753-16
pubmed: 27185800
pmcid: 4958187
Andries K, et al. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS ONE. 2014;9:e102135. https://doi.org/10.1371/journal.pone.0102135 .
doi: 10.1371/journal.pone.0102135
pubmed: 25010492
pmcid: 4092087
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58:2979–81. https://doi.org/10.1128/AAC.00037-14 .
doi: 10.1128/AAC.00037-14
pubmed: 24590481
pmcid: 3993252
Poulton NC, Azadian ZA, DeJesus MA, Rock JM. Mutations in rv0678 confer low-level resistance to Benzothiazinone DprE1 inhibitors in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022;66:e0090422. https://doi.org/10.1128/aac.00904-22 .
doi: 10.1128/aac.00904-22
pubmed: 35920665
Vargas R Jr, et al. Role of epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine resistance in Mycobacterium tuberculosis Complex. Antimicrob Agents Chemother. 2021;65:e0116421. https://doi.org/10.1128/AAC.01164-21 .
doi: 10.1128/AAC.01164-21
pubmed: 34460306
Bloemberg GV, et al. Acquired resistance to Bedaquiline and Delamanid in therapy for Tuberculosis. N Engl J Med. 2015;373:1986–8. https://doi.org/10.1056/NEJMc1505196 .
doi: 10.1056/NEJMc1505196
pubmed: 26559594
pmcid: 4681277
Xu J. et al. Primary Clofazimine and Bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2017;61. https://doi.org/10.1128/AAC.00239-17
Zimenkov DV, et al. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region. J Antimicrob Chemother. 2017;72:1901–6. https://doi.org/10.1093/jac/dkx094 .
doi: 10.1093/jac/dkx094
pubmed: 28387862
de Vos M, et al. Bedaquiline microheteroresistance after cessation of Tuberculosis treatment. N Engl J Med. 2019;380:2178–80. https://doi.org/10.1056/NEJMc1815121 .
doi: 10.1056/NEJMc1815121
pubmed: 31141643
pmcid: 6518951
Ghodousi A. et al. Acquisition of cross-resistance to Bedaquiline and Clofazimine following treatment for Tuberculosis in Pakistan. Antimicrob Agents Chemother 2019;63. https://doi.org/10.1128/AAC.00915-19
Polsfuss S, et al. Emergence of low-level delamanid and Bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin Infect Dis. 2019;69:1229–31. https://doi.org/10.1093/cid/ciz074 .
doi: 10.1093/cid/ciz074
pubmed: 30933266
Mokrousov I, Akhmedova G, Polev D, Molchanov V, Vyazovaya A. Acquisition of bedaquiline resistance by extensively drug-resistant Mycobacterium tuberculosis strain of Central Asian outbreak clade. Clin Microbiol Infect. 2019;25:1295–7. https://doi.org/10.1016/j.cmi.2019.06.014 .
doi: 10.1016/j.cmi.2019.06.014
pubmed: 31229592
Kadura S, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother. 2020;75:2031–43. https://doi.org/10.1093/jac/dkaa136 .
doi: 10.1093/jac/dkaa136
pubmed: 32361756
pmcid: 7825472
Roberts LW. et al. Repeated evolution of bedaquiline resistance in Mycobacterium tuberculosis is driven by truncation of mmpR5. bioRxiv, 2022.2012.2008.519610. 2022. https://doi.org/10.1101/2022.12.08.519610
Sonnenkalb L, et al. Bedaquiline and clofazimine resistance in Mycobacterium tuberculosis: an in-vitro and in-silico data analysis. Lancet Microbe. 2023;4:e358–68. https://doi.org/10.1016/S2666-5247(23)00002-2 .
doi: 10.1016/S2666-5247(23)00002-2
pubmed: 37003285
pmcid: 10156607
Ismail N, et al. Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis. Lancet Microbe. 2021;2:E604–16. https://doi.org/10.1016/S2666-5247(21)00175-0 .
doi: 10.1016/S2666-5247(21)00175-0
pubmed: 34796339
pmcid: 8597953
World Health Organization. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. 2023. https://iris.who.int/handle/10665/374061 . Accessed 31 Jan 2024.
World Health Organization. Technical report on critical concentrations for TB drug susceptibility testing of medicines used in the treatment of drug-resistant TB. 2018.
Nimmo C. et al. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients. Eur Respir J 2020;55. https://doi.org/10.1183/13993003.02383-2019
Martinez E, et al. Mutations associated with in vitro resistance to Bedaquiline in Mycobacterium tuberculosis isolates in Australia. Tuberculosis (Edinb). 2018;111:31–4. https://doi.org/10.1016/j.tube.2018.04.007 .
doi: 10.1016/j.tube.2018.04.007
pubmed: 30029911
Timm J, et al. Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLOS Glob Public Health. 2023;3:e0002283. https://doi.org/10.1371/journal.pgph.0002283 .
doi: 10.1371/journal.pgph.0002283
pubmed: 37851685
pmcid: 10584172
Villellas C, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2017;72:684–90. https://doi.org/10.1093/jac/dkw502 .
doi: 10.1093/jac/dkw502
pubmed: 28031270
Merker M, et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020;12:27. https://doi.org/10.1186/s13073-020-00726-5 .
doi: 10.1186/s13073-020-00726-5
pubmed: 32143680
pmcid: 7060619
Coll F, et al. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812. https://doi.org/10.1038/ncomms5812 .
doi: 10.1038/ncomms5812
pubmed: 25176035
Sobkowiak B, et al. Identifying mixed Mycobacterium tuberculosis infections from whole genome sequence data. BMC Genomics. 2018;19:613. https://doi.org/10.1186/s12864-018-4988-z .
doi: 10.1186/s12864-018-4988-z
pubmed: 30107785
pmcid: 6092779
Brynildsrud OB, et al. Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation. Sci Adv. 2018;4:eaat5869.
doi: 10.1126/sciadv.aat5869
pubmed: 30345355
pmcid: 6192687
Bradley P, den Bakker HC, Rocha EPC, McVean G, Iqbal Z. Ultrafast search of all deposited bacterial and viral genomic data. Nat Biotechnol. 2019;37:152–9. https://doi.org/10.1038/s41587-018-0010-1 .
doi: 10.1038/s41587-018-0010-1
pubmed: 30718882
pmcid: 6420049
Merker M, et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet. 2015;47:242–9. https://doi.org/10.1038/ng.3195 .
doi: 10.1038/ng.3195
pubmed: 25599400
Luo T, et al. Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese. Proc Natl Acad Sci U S A. 2015;112:8136–41. https://doi.org/10.1073/pnas.1424063112 .
doi: 10.1073/pnas.1424063112
pubmed: 26080405
pmcid: 4491734
Norheim G, et al. Tuberculosis outbreak in an educational institution in Norway. J Clin Microbiol. 2017;55:1327–33. https://doi.org/10.1128/JCM.01152-16 .
doi: 10.1128/JCM.01152-16
pubmed: 28202795
pmcid: 5405251
Kay GL, et al. Eighteenth-century genomes show that mixed infections were common at time of peak tuberculosis in Europe. Nat Commun. 2015;6:6717. https://doi.org/10.1038/ncomms7717 .
doi: 10.1038/ncomms7717
pubmed: 25848958
Nimmo C, et al. Population-level emergence of bedaquiline and clofazimine resistance-associated variants among patients with drug-resistant tuberculosis in southern Africa: a phenotypic and phylogenetic analysis. Lancet Microbe. 2020;1:e165–74. https://doi.org/10.1016/S2666-5247(20)30031-8 .
doi: 10.1016/S2666-5247(20)30031-8
pubmed: 32803174
pmcid: 7416634
Nimmo C, et al. Dynamics of within-host Mycobacterium tuberculosis diversity and heteroresistance during treatment. EBioMedicine. 2020;55:102747. https://doi.org/10.1016/j.ebiom.2020.102747 .
doi: 10.1016/j.ebiom.2020.102747
pubmed: 32361247
pmcid: 7195533
Nimmo C, et al. Whole genome sequencing Mycobacterium tuberculosis directly from sputum identifies more genetic diversity than sequencing from culture. BMC Genomics. 2019;20:389. https://doi.org/10.1186/s12864-019-5782-2 .
doi: 10.1186/s12864-019-5782-2
pubmed: 31109296
pmcid: 6528373
Dheda K, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med. 2017;5:269–81. https://doi.org/10.1016/S2213-2600(16)30433-7 .
doi: 10.1016/S2213-2600(16)30433-7
pubmed: 28109869
Streicher EM, et al. Molecular epidemiological interpretation of the epidemic of extensively drug-resistant Tuberculosis in South Africa. J Clin Microbiol. 2015;53:3650–3. https://doi.org/10.1128/JCM.01414-15 .
doi: 10.1128/JCM.01414-15
pubmed: 26338863
pmcid: 4609696
Guerra-Assuncao JA. et al. Large-scale whole genome sequencing of M. tuberculosis provides insights into transmission in a high prevalence area. Elife 2015;4. https://doi.org/10.7554/eLife.05166
Grandjean L, et al. Transmission of multidrug-resistant and drug-susceptible Tuberculosis within households: a prospective cohort study. PLoS Med. 2015;12:e1001843. https://doi.org/10.1371/journal.pmed.1001843 . discussion e1001843.
doi: 10.1371/journal.pmed.1001843
pubmed: 26103620
pmcid: 4477882
Grandjean L, et al. Convergent evolution and topologically disruptive polymorphisms among multidrug-resistant tuberculosis in Peru. PLoS ONE. 2017;12:e0189838. https://doi.org/10.1371/journal.pone.0189838 .
doi: 10.1371/journal.pone.0189838
pubmed: 29281674
pmcid: 5744980
Ismail N, Omar SV, Ismail NA, Peters RPH. Collated data of mutation frequencies and associated genetic variants of bedaquiline, clofazimine and linezolid resistance in Mycobacterium tuberculosis. Data Brief. 2018;20:1975–83. https://doi.org/10.1016/j.dib.2018.09.057 .
doi: 10.1016/j.dib.2018.09.057
pubmed: 30306102
pmcid: 6172430
Ghajavand H. et al. High prevalence of Bedaquiline resistance in treatment-naive tuberculosis patients and Verapamil effectiveness. Antimicrob Agents Chemother 2019;63. https://doi.org/10.1128/AAC.02530-18
Fowler PW. 2017 pygsi v.1.0.0: a Python class to interrogate BIGISI. 2018. https://doi.org/10.5281/zenodo.1407085 .
Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv 2013. arXiv:1303.3997
Van der Auwera GA, et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;11(10):11–111033. https://doi.org/10.1002/0471250953.bi1110s43 .
doi: 10.1002/0471250953.bi1110s43
pmcid: 4243306
Okonechnikov K, Conesa A, Garcia-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics. 2016;32:292–4. https://doi.org/10.1093/bioinformatics/btv566 .
doi: 10.1093/bioinformatics/btv566
pubmed: 26428292
Hariguchi N. et al. OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 Inhibitor. Antimicrob Agents Chemother 2020;64. https://doi.org/10.1128/AAC.02020-19
Phelan JE, et al. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med. 2019;11:41. https://doi.org/10.1186/s13073-019-0650-x .
doi: 10.1186/s13073-019-0650-x
pubmed: 31234910
pmcid: 6591855
Coll F, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 2015;7:51. https://doi.org/10.1186/s13073-015-0164-0 .
doi: 10.1186/s13073-015-0164-0
pubmed: 26019726
pmcid: 4446134
The Cryptic Consortium. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics. PLoS Biol. 2022;20:e3001721. https://doi.org/10.1371/journal.pbio.3001721 .
doi: 10.1371/journal.pbio.3001721
pmcid: 9363010
Page AJ, et al. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. Microb Genom. 2016;2:e000056. https://doi.org/10.1099/mgen.0.000056 .
doi: 10.1099/mgen.0.000056
pubmed: 28348851
pmcid: 5320690
Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. RAxML-NG: a fast, scalable and user-friendly tool for maximum likelihood phylogenetic inference. Bioinformatics. 2019;35:4453–5. https://doi.org/10.1093/bioinformatics/btz305 .
doi: 10.1093/bioinformatics/btz305
pubmed: 31070718
pmcid: 6821337
Didelot X, Croucher NJ, Bentley SD, Harris SR, Wilson DJ. Bayesian inference of ancestral dates on bacterial phylogenetic trees. Nucleic Acids Res. 2018;46:e134. https://doi.org/10.1093/nar/gky783 .
doi: 10.1093/nar/gky783
pubmed: 30184106
pmcid: 6294524
Menardo F, et al. Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity. BMC Bioinformatics. 2018;19:164. https://doi.org/10.1186/s12859-018-2164-8 .
doi: 10.1186/s12859-018-2164-8
pubmed: 29716518
pmcid: 5930393
Bouckaert R, et al. BEAST 2.5: An advanced software platform for Bayesian evolutionary analysis. PLoS Comput Biol. 2019;15:e1006650. https://doi.org/10.1371/journal.pcbi.1006650 .
doi: 10.1371/journal.pcbi.1006650
pubmed: 30958812
pmcid: 6472827
Bouckaert RR, Drummond AJ. bModelTest: Bayesian phylogenetic site model averaging and model comparison. BMC Evol Biol. 2017;17:42. https://doi.org/10.1186/s12862-017-0890-6 .
doi: 10.1186/s12862-017-0890-6
pubmed: 28166715
pmcid: 5294809
Baele G, et al. Improving the accuracy of demographic and molecular clock model comparison while accommodating phylogenetic uncertainty. Mol Biol Evol. 2012;29:2157–67. https://doi.org/10.1093/molbev/mss084 .
doi: 10.1093/molbev/mss084
pubmed: 22403239
pmcid: 3424409
Paradis E, Schliep K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics. 2019;35:526–8. https://doi.org/10.1093/bioinformatics/bty633 .
doi: 10.1093/bioinformatics/bty633
pubmed: 30016406
Yu GC, Smith DK, Zhu HC, Guan Y, Lam TTY. GGTREE: an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. Methods Ecol Evol. 2017;8:28–36. https://doi.org/10.1111/2041-210x.12628 .
doi: 10.1111/2041-210x.12628
O’Neill MB, et al. Lineage specific histories of Mycobacterium tuberculosis dispersal in Africa and Eurasia. Mol Ecol. 2019;28:3241–56. https://doi.org/10.1111/mec.15120 .
doi: 10.1111/mec.15120
pubmed: 31066139
pmcid: 6660993
Rutaihwa LK, et al. Multiple Introductions of Mycobacterium tuberculosis lineage 2-Beijing into Africa over centuries. Front Ecol Evol. 2019;7:ARTN 112. https://doi.org/10.3389/fevo.2019.00112 .
doi: 10.3389/fevo.2019.00112
Bradley P, et al. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun. 2015;6:10063. https://doi.org/10.1038/ncomms10063 .
doi: 10.1038/ncomms10063
pubmed: 26686880
Menardo F, Duchene S, Brites D, Gagneux S. The molecular clock of Mycobacterium tuberculosis. PLoS Pathog. 2019;15:e1008067. https://doi.org/10.1371/journal.ppat.1008067 .
doi: 10.1371/journal.ppat.1008067
pubmed: 31513651
pmcid: 6759198
Ismail N, Peters RPH, Ismail NA, Omar SV. Clofazimine exposure in vitro selects efflux pump mutants and Bedaquiline resistance. Antimicrob Agents Chemother 2019;63. https://doi.org/10.1128/AAC.02141-18
Andres S, et al. Bedaquiline-resistant tuberculosis: dark clouds on the horizon. Am J Respir Crit Care Med. 2020;201:1564–8. https://doi.org/10.1164/rccm.201909-1819LE .
doi: 10.1164/rccm.201909-1819LE
pubmed: 32053752
The Cryptic Consortium. Epidemiological cutoff values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis. Eur Respir J 2022;2200239. https://doi.org/10.1183/13993003.00239-2022
Rancoita PMV. et al. Validating a 14-drug microtiter plate containing Bedaquiline and Delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2018;62. https://doi.org/10.1128/AAC.00344-18
Beckert P, et al. MDR M. tuberculosis outbreak clone in Eswatini missed by Xpert has elevated bedaquiline resistance dated to the pre-treatment era. Genome Med. 2020;12:104. https://doi.org/10.1186/s13073-020-00793-8 .
doi: 10.1186/s13073-020-00793-8
pubmed: 33239092
pmcid: 7687760
Loiseau C, et al. An African origin for Mycobacterium bovis. Evol Med Public Health. 2020;2020:49–59. https://doi.org/10.1093/emph/eoaa005 .
doi: 10.1093/emph/eoaa005
pubmed: 32211193
pmcid: 7081938
Bateson A, et al. Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. J Antimicrob Chemother. 2022;77:1685–93. https://doi.org/10.1093/jac/dkac070 .
doi: 10.1093/jac/dkac070
pubmed: 35260883
pmcid: 9155602
D’Costa VM, et al. Antibiotic resistance is ancient. Nature. 2011;477:457–61. https://doi.org/10.1038/nature10388 .
doi: 10.1038/nature10388
pubmed: 21881561
Rifat D, et al. Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis. Antimicrob Agents Ch. 2021;65:ARTN e01948–20. https://doi.org/10.1128/AAC.01948-20 .
doi: 10.1128/AAC.01948-20
Koser CU, Maurer FP. Minimum inhibitory concentrations and sequencing data have to be analysed in more detail to set provisional epidemiological cut-off values for Mycobacterium tuberculosis complex. Eur Respir J 2023;61. https://doi.org/10.1183/13993003.02397-2022
Kahlmeter G, Turnidge J. The determination of epidemiological cut-off values requires a systematic and joint approach based on quality controlled, non-truncated minimum inhibitory concentration series. Eur Respir J 2023;61. https://doi.org/10.1183/13993003.02259-2022
World Health Organization. Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex. 2022. https://iris.who.int/handle/10665/353066 .
Liu Y, et al. Reduced susceptibility of Mycobacterium tuberculosis to Bedaquiline during antituberculosis treatment and its correlation with clinical outcomes in China. Clin Infect Dis. 2021;73:e3391–7. https://doi.org/10.1093/cid/ciaa1002 .
doi: 10.1093/cid/ciaa1002
pubmed: 32667984
Pym AS, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47:564–74. https://doi.org/10.1183/13993003.00724-2015 .
doi: 10.1183/13993003.00724-2015
pubmed: 26647431
Grandjean L, et al. The association between Mycobacterium Tuberculosis genotype and drug resistance in Peru. PLoS ONE. 2015;10: e0126271. https://doi.org/10.1371/journal.pone.0126271 .
doi: 10.1371/journal.pone.0126271
pubmed: 25984723
pmcid: 4435908